Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease.

Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque EX.

Behav Brain Res. 2000 Aug;113(1-2):199-206. Review.

PMID:
10942046
2.

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease.

Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, Zerlin M.

Biol Psychiatry. 2001 Feb 1;49(3):279-88. Review.

PMID:
11230879
3.

Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.

Maelicke A.

Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:11-8. Review.

PMID:
10971047
4.

Potential applications of nicotinic ligands in the laboratory and clinic.

Dani JA, De Biasi M, Liang Y, Peterson J, Zhang L, Zhang T, Zhou FM.

Bioorg Med Chem Lett. 2004 Apr 19;14(8):1837-9. Review.

PMID:
15050611
5.

Nicotinic cholinergic modulation: galantamine as a prototype.

Woodruff-Pak DS, Lander C, Geerts H.

CNS Drug Rev. 2002 Winter;8(4):405-26. Review.

6.

Nicotinic acetylcholine involvement in cognitive function in animals.

Levin ED, Simon BB.

Psychopharmacology (Berl). 1998 Aug;138(3-4):217-30. Review.

PMID:
9725745
7.

Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach.

Grupe M, Grunnet M, Bastlund JF, Jensen AA.

Basic Clin Pharmacol Toxicol. 2015 Mar;116(3):187-200. doi: 10.1111/bcpt.12361. Epub 2014 Dec 29. Review.

8.

Nicotinic receptor modulation: advantages for successful Alzheimer's disease therapy.

Geerts H, Finkel L, Carr R, Spiros A.

J Neural Transm Suppl. 2002;(62):203-16. Review.

PMID:
12456064
9.

Mechanisms of action of cognitive enhancers on neuroreceptors.

Narahashi T, Moriguchi S, Zhao X, Marszalec W, Yeh JZ.

Biol Pharm Bull. 2004 Nov;27(11):1701-6. Review.

10.

Multiple actions of THA on cholinergic neurotransmission in Alzheimer brains.

Nordberg A, Nilsson-Håkansson L, Adem A, Lai Z, Winblad B.

Prog Clin Biol Res. 1989;317:1169-78. Review.

PMID:
2557636
11.
12.

Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications.

Nordberg A.

Biol Psychiatry. 2001 Feb 1;49(3):200-10. Review.

PMID:
11230871
13.

Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J.

Drugs Aging. 2004;21(7):453-78. Review.

PMID:
15132713
15.

Overview of nicotinic receptors and their roles in the central nervous system.

Dani JA.

Biol Psychiatry. 2001 Feb 1;49(3):166-74. Review.

PMID:
11230867
16.

Noncompetitive agonism at nicotinic acetylcholine receptors; functional significance for CNS signal transduction.

Maelicke A, Schrattenholz A, Storch A, Schroder B, Gutbrod O, Methfessel C, Weber KH, Pereira EE, Alkondon M, Albuquerque EX.

J Recept Signal Transduct Res. 1995 Jan-Mar;15(1-4):333-53. Review.

PMID:
8903949
17.
18.

[Nicotinic acetylcholine receptor in Alzheimer's disease].

Abe K.

Nihon Rinsho. 2013 Apr;71(4):743-50. Review. Japanese.

PMID:
23678610
20.

Reappraising neurotransmitter-based strategies.

Möller HJ.

Eur Neuropsychopharmacol. 1999 Apr;9 Suppl 2:S53-9. Review.

PMID:
10332935

Supplemental Content

Support Center